RTP Mobile Logo
Striving for Consensus: The Application of Existing and Emerging Research Findings to the Practical Management of Hodgkin and Non-Hodgkin Lymphoma (Video Program)
Released November 2013

Video excerpts from a clinical investigator Think Tank held on July 19, 2013. Featuring perspectives from Drs Andrew M Evens, Christopher Flowers, Jonathan W Friedberg, Julie M Vose and Michael E Williams. (Video Program)

CE Disclosures and Faculty Information

    This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hematologic cancers.

    Non-Hodgkin lymphoma (NHL) comprises a heterogeneous group of lymphoproliferative disorders and is one of the most rapidly evolving fields in hematology and oncology. In contrast, Hodgkin lymphoma (HL) is a rarer disease that is relatively chemosensitive and often curable when treated appropriately. However, care for patients who do not respond to primary treatment or those with relapsed or refractory HL remains a significant challenge for oncology clinicians. Published results from ongoing clinical trials lead to the continual emergence of new therapeutic agents and changes in the use of existing treatments. To offer optimal patient care — including the option of clinical trial participation — practicing medical oncologists, hematologists and hematology-oncology fellows must be well informed of these advances. This program uses a roundtable discussion with leading clinical investigators to assist practicing clinicians in formulating up-to-date clinical management strategies for NHL, HL and chronic lymphocytic leukemia (CLL).


    • Develop an understanding of emerging efficacy and side-effect data with novel agents and combination regimens under evaluation for indolent and aggressive B-cell and T-cell NHL.
    • Incorporate new therapeutic strategies into the best-practice management of HL.
    • Develop an algorithm for the evaluation and treatment of newly diagnosed and relapsed/refractory CLL.
    • Devise an evidence-based approach to the sequential systemic treatment of peripheral T-cell lymphoma.
    • Use available research evidence and understand the controversies surrounding the use of CNS prophylaxis to guide treatment decision-making for patients with diffuse large B-cell lymphoma.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CME activity consists of a video component. The participant should watch the video.

    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Andrew M Evens, DO, MSc
    Professor of Medicine
    Chief, Division of Hematology/Oncology
    Tufts University School of Medicine
    Director, Lymphoma Program
    Leader, Clinical Sciences Program
    Tufts Cancer Center
    Boston, Massachusetts

    Advisory Committee: Millennium: The Takeda Oncology Company, Seattle Genetics, Spectrum Pharmaceuticals Inc; Contracted Research: Millennium: The Takeda Oncology Company, ZIOPHARM Oncology Inc.

    Christopher Flowers, MD, MS
    Associate Professor of Hematology
    and Medical Oncology
    Emory School of Medicine
    Winship Cancer Institute
    Atlanta, Georgia

    Consulting Agreements: Celgene Corporation, Genentech BioOncology; Contracted Research: Abbott Laboratories, Janssen Pharmaceuticals Inc, Millennium: The Takeda Oncology Company, Sanofi, Spectrum Pharmaceuticals Inc.

    Jonathan W Friedberg, MD, MMSc
    Samuel Durand Professor of Medicine
    Director, Wilmot Cancer Center
    University of Rochester
    Rochester, New York

    Advisory Committee: Genentech BioOncology; Data and Safety Monitoring Board: Lilly.

    Julie M Vose, MD, MBA
    Neumann M and Mildred E Harris Professor
    Chief, Division of Hematology/Oncology
    Professor of Medicine
    Nebraska Medical Center
    Omaha, Nebraska

    Contracted Research: Allos Therapeutics, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Incyte Corporation, Janssen Pharmaceuticals Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, OncoMed Pharmaceuticals Inc, Onyx Pharmaceuticals Inc, Pharmacyclics Inc, Sanofi, US Biotest Inc.

    Michael E Williams, MD, ScM
    Byrd S Leavell Professor of Medicine
    Chief, Hematology/Oncology Division
    University of Virginia School of Medicine
    Charlottesville, Virginia

    Advisory Committee: Celgene Corporation, Genentech BioOncology, Janssen Pharmaceuticals Inc, Onyx Pharmaceuticals Inc; Consulting Agreements: Celgene Corporation, Millennium: The Takeda Oncology Company; Contracted Research: Allos Therapeutics, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Pharmacyclics Inc.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Genentech BioOncology/Biogen Idec, Lilly, Millennium: The Takeda Oncology Company, Seattle Genetics and Spectrum Pharmaceuticals Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: November 2013
    Expiration date: November 2014

Acknowledge and close

Watch video
(WIFI is recommended for best performance):

Hodgkin lymphoma (HL)
Brentuximab vedotin as a bridge to transplant in HL
Phase III trial of brentuximab vedotin as part of up-front treatment of HL
Routine surveillance scanning in HL
Case presentation: 34-year-old woman with relapsed HL who received brentuximab vedotin for progression after autotransplant
Case presentation: 87-year-old woman with advanced-stage HL
Case presentation: A young woman with bulky mediastinal HL and a BRCA germline mutation
Chronic lymphocytic leukemia (CLL)
Phase III CLL11 trial: Obinutuzumab combined with chlorambucil
Lenalidomide in CLL
Case presentation: 65-year-old physician with refractory CLL, autoimmune hemolytic anemia and 17p deletion
Follicular lymphoma (FL)
ECOG trial 2408 in high-risk FL evaluating BR + bortezomib as part of induction and lenalidomide + R as part of maintenance
Radioimmunotherapy consolidation after R/chemo in indolent lymphoma
Case presentation: 48-year-old woman with FL with disease progression after a prolonged response to R monotherapy as second-line therapy
Mantle-cell lymphoma (MCL)
Small-molecule B-cell receptor inhibitors: ibrutinib
Case presentation: 77-year-old man with MCL with a complete response to BR now considering R maintenance or RIT consolidation
Diffuse large B-cell lymphoma (DLBCL)
R-CHOP with lenalidomide in DLBCL
Case presentation: 88-year-old man with DLBCL of the floor of the maxillary sinus
Case presentation: 67-year-old man with “double-hit” DLBCL
Case presentation: 28-year-old woman with primary mediastinal DLBCL
T-cell lymphoma (TCL)
Belinostat, a new HDAC inhibitor with activity in relapsed/refractory peripheral TCL
Case presentation: 76-year-old man who received pralatrexate for relapsed peripheral TCL NOS
Case presentation: 61-year-old man who received brentuximab vedotin for relapsed ALK-negative anaplastic large cell lymphoma